AbbVie Management

Management criteria checks 2/4

AbbVie's CEO ist Rick Gonzalez , ernannt in Jan 2013, hat eine Amtszeit von 11.08 Jahren. Die jährliche Gesamtvergütung beträgt $26.29M , bestehend aus 6.5% Gehalt und 93.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.031% der Aktien des Unternehmens, im Wert von $90.88M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.1 Jahre bzw. 11.1 Jahre.

Key information

Rick Gonzalez

Chief executive officer

US$25.7m

Total compensation

CEO salary percentage	6.6%
CEO tenure	11.3yrs
CEO ownership	0.03%
Management average tenure	1.4yrs
Board average tenure	11.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rick Gonzalez's remuneration changed compared to AbbVie's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$26m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$26m	US$2m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$24m	US$2m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$24m	US$2m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$22m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$21m	US$2m	US$6b
Sep 30 2018	n/a	n/a	US$8b
Jun 30 2018	n/a	n/a	US$6b
Mar 31 2018	n/a	n/a	US$6b
Dec 31 2017	US$23m	US$2m	US$5b

Vergütung im Vergleich zum Markt: RickDie Gesamtvergütung ($USD26.29M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt AR ($USD5.70M).

Entschädigung vs. Einkommen: RickDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

CEO

Rick Gonzalez (69 yo)

11.3yrs

Tenure

US$25,661,972

Compensation

Mr. Richard A. Gonzalez, also known as Rick, serves as Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of Phar...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Gonzalez	Chairman & CEO	11.3yrs	US$25.66m	0.031% $ 93.3m
Robert Michael	President & COO	1.8yrs	US$14.44m	0.0056% $ 16.8m
Scott Reents	Executive VP & CFO	1.8yrs	US$10.19m	0.00087% $ 2.6m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.013% $ 38.4m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% $ 10.6m
Thomas Hudson	Senior VP & Chief Scientific Officer of Global Research	no data	no data	0.0061% $ 18.2m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	no data	no data
Perry Siatis	Executive VP	1.5yrs	no data	0% $ 0
Sanjay Narayan	Senior VP	less than a year	no data	no data
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% $ 2.3m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	less than a year	no data	no data
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.3yrs	no data	0.0032% $ 9.5m

1.4yrs

Average Tenure

55yo

Average Age

Erfahrenes Management: ABBVDDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Gonzalez	Chairman & CEO	11.3yrs	US$25.66m	0.031% $ 93.3m
Roxanne Austin	Independent Director	11.3yrs	US$385.59k	0.00065% $ 2.0m
Thomas Freyman	Independent Director	3.9yrs	US$380.78k	0.0071% $ 21.3m
Glenn Tilton	Lead Independent Director	11.3yrs	US$418.94k	0.0014% $ 4.2m
Edward Rapp	Independent Director	11.3yrs	US$394.98k	0.00090% $ 2.7m
William H. Burnside	Independent Director	11.3yrs	US$377.48k	0% $ 0
Frederick Waddell	Independent Director	11.3yrs	US$369.98k	0.00011% $ 331.1k
Melody Meyer	Independent Director	6.9yrs	US$369.98k	0% $ 0
Brett Hart	Independent Director	8.3yrs	US$380.78k	0% $ 0
Rebecca Roberts	Independent Director	5.9yrs	US$359.98k	no data
Robert Alpern	Independent Director	11.3yrs	US$461.18k	0.000010% $ 30.1k
Jennifer Davis	Independnet Director	less than a year	no data	no data

11.3yrs

Average Tenure

69yo

Average Age

Erfahrener Vorstand: ABBVDDie Vorstandsmitglieder sind sehr erfahren ( 10.9 ).

AbbVie Management

Management criteria checks 2/4

Key information

Recent management updates

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie Inc. Announces Chief Executive Officer Changes

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Appoints Robert A. Michael as President and Chief Operating Officer

Recent updates

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie Inc. (NYSE:ABBV) acquired Mitokinin, Inc. for $655 million.

AbbVie Inc. to Report Q3, 2023 Results on Oct 27, 2023

Abbvie Presents Results from Phase 3 Canova Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Abbvie Inc. Announces Top-Line Results from the Phase 3 Sequence Clinical Trial Evaluating Risankizumab

AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2023

AbbVie Inc. Submits Regulatory Applications to FDA and Ema for Risankizumab (Skyrizi®) in Ulcerative Colitis

Abbvie Inc. Announces European Commission Approves AQUIPTA for the Prophylaxis of Migraine in Adults

AbbVie Announces the British Journal of Dermatology Publishes Results from the Head-To-Head Phase 4 IMMpulse Study

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AbbVie Inc. to Report Q2, 2023 Results on Jul 27, 2023

AbbVie Inc. Appoints Robert A. Michael as President and Chief Operating Officer

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine

AbbVie Inc. Declares Quarterly Dividend, Payable on August 15, 2023

Abbvie Inc. Announces Risankizumab (Skyrizi®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

AbbVie Inc. Announces New Findings Demonstrating Sustained Long-Term Safety and Efficacy of Venclyxto®?/Venclexta

Abbvie Announces the Results of the Phase 2 Sleek Study Evaluating Upadacitinib (Rinvoq®?) Alone and in Combination Therapy

Abbvie Inc. Announces New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib in Crohn's Disease

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age